Relationship between the serum cancer antigen 125 level and the weight of surgically enucleated adenomyosis
article
OA: closed
CC0
⤵ 7 in-corpus citations
AI-generated summary
This study found a positive correlation between serum cancer antigen 125 levels and the weight of surgically removed adenomyosis in 308 patients.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Elevated serum levels of cancer antigen 125 (CA125) are known to occur in adenomyosis. However, the relationship between the severity of adenomyosis and serum CA125 levels has not yet been elucidated. The present study aimed to examine the correlation between the weight of adenomyosis and the serum CA125 level. This retrospective study, after applying exclusion criteria, investigated 308 patients who underwent conservative surgery for adenomyosis. Serum CA125 levels were measured before surgery and weights of surgically enucleated adenomyosis were measured in the operating room. Both serum CA125 and surgically enucleated adenomyosis weight showed log-normal distributions. Pearson’s product-moment correlation coefficient for the logarithmically converted values was 0.617 (95% confidence interval, 0.54–0.68).The serum CA125 level correlated positively with the weight of adenomyosis. Although the qualitative characteristics and clinical significance of adenomyosis lesions remain unclear, it seems that the investigation of the relative relationship between the serum CA125 level and the size of the affected lesion is useful to observe one of the qualitative features of adenomyosis. Furthermore, the present study supports the use of postoperative serum CA125 levels as an important indicator for determining the therapeutic effects of conservative surgical treatment for adenomyosis and detecting early signs of recurrence. Impact StatementWhat is already known on this subject? Elevated serum cancer antigen 125 (CA125) levels are known to occur in adenomyosis and are widely recognised as helpful in the diagnosis of adenomyosis.What do the results of this study add? There is a positive correlation between the serum CA125 level and the weight of adenomyosis.What are the implications of these findings for clinical practice and/or further research? The postoperative serum CA125 level is an important indicator for evaluating the extent of the affected lesion remaining after conservative surgical treatment for adenomyosis and also helpful for detecting early signs of recurrence. Further study is required to examine whether it is possible to clarify the qualitative characteristics of adenomyosis in each different case based on the CA125-producing ability of the lesion.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (14)
- Cancer antigen 125 is produced by human endometrial stromal cells* via openalex
- Clinical evaluation of CA-125 concentrations as a prognostic factor for pregnancy in infertile women with surgically treated endometriosis via openalex
- Conservative Surgery in the Management of Adenomyosis via openalex
- Conservative surgical management for diffuse uterine adenomyosis via openalex
- Pathophysiology of adenomyosis via openalex
- Serum CA-125 antigen levels increase during menses via openalex
- Severe adenomyosis and CA125 via openalex
- W2110063500 via openalex
- W1978246084 via openalex
- W1992973720 via openalex
- W2030547331 via openalex
- W59117347 via openalex
- W2164796316 via openalex
- W2283760758 via openalex
Cited by (7)
- Identification of diagnostic blood indicators associated with adenomyosis: a retrospective cohort study 2026
- Changes of serum CA125 and PGE2 before and after high-intensity focused ultrasound combined with GnRH-a in treatment of patients with adenomyosis 2024
- Effect of Gonadotropin‐Releasing Hormone Agonist Pre‐Treatment on Outcomes of Fresh and Frozen Embryo Transfers in Women With Adenomyosis: A Retrospective Cohort Study With Literature Review 2024
- Efficacy and safety of dienogest versus GnRH-a combined with dienogest therapy for adenomyosis 2023
- Clinical efficacy of a novel method of fertility-preserving adenomyomectomy in infertile women with diffuse adenomyosis 2023
- Maintenance dienogest therapy following adjuvant gonadotropin‐releasing hormone agonist treatment after uterus‐sparing surgery in adenomyosis: A retrospective cohort study 2022
- Meta-Analysis on the Therapeutic Effectiveness of Dienogest plus GnRH Agonist in Treating Adenomyosis and Its Related Obstetric Risk Factors 2021
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-17T00:34:32.041701+00:00
License: CC0
· commercial use OK